Ismail Cem Sormaz1, Arzu Poyanlı2, Sami Açar3, Ahmet Yalın İşcan4, İlker Ozgur3, Fatih Tunca3, Yasemin Giles Senyürek3. 1. Istanbul Faculty of Medicine, Department of General Surgery, Istanbul University, Millet Caddesi Capa, Fatih, 34093, Istanbul, Turkey. icsormaz@gmail.com. 2. Istanbul Faculty of Medicine, Department of Radiology, Istanbul University, Istanbul, Turkey. 3. Istanbul Faculty of Medicine, Department of General Surgery, Istanbul University, Millet Caddesi Capa, Fatih, 34093, Istanbul, Turkey. 4. Department of General Surgery, Fatih Sultan Mehmet Research and Education Hospital, Istanbul, Turkey.
Abstract
BACKGROUND: The aim of the study was to evaluate the results of ultrasonography (US)-guided percutaneous radiofrequency ablation (RFA) in hyperparathyroid patients who refused surgery or had high surgical risks. PATIENTS AND METHODS: Five patients with hyperparathyroidism (HPT) underwent US-guided RFA for a single hyperfunctioning parathyroid lesion. Post-ablation serum calcium and parathormone (PTH) assays were performed. All patients underwent imaging studies 6 months after the ablation to visualize the post-ablation change in the size of the treated parathyroid lesions. RESULTS: All patients were normocalcemic on the post-ablation 1st day and 6th month. The post-ablation PTH levels were normal in three patients but remained elevated in two patients. The size of the parathyroid lesion was ≥30 mm in the two patients with elevated PTH, whereas the lesion was smaller than 30 mm in those with normal post-ablation PTH values. CONCLUSION: Although this is a limited case series, it demonstrates the potential feasibility of RFA for HPT. Benefits were achieved particularly in patients with small parathyroid lesions.
BACKGROUND: The aim of the study was to evaluate the results of ultrasonography (US)-guided percutaneous radiofrequency ablation (RFA) in hyperparathyroidpatients who refused surgery or had high surgical risks. PATIENTS AND METHODS: Five patients with hyperparathyroidism (HPT) underwent US-guided RFA for a single hyperfunctioning parathyroid lesion. Post-ablation serum calcium and parathormone (PTH) assays were performed. All patients underwent imaging studies 6 months after the ablation to visualize the post-ablation change in the size of the treated parathyroid lesions. RESULTS: All patients were normocalcemic on the post-ablation 1st day and 6th month. The post-ablation PTH levels were normal in three patients but remained elevated in two patients. The size of the parathyroid lesion was ≥30 mm in the two patients with elevated PTH, whereas the lesion was smaller than 30 mm in those with normal post-ablation PTH values. CONCLUSION: Although this is a limited case series, it demonstrates the potential feasibility of RFA for HPT. Benefits were achieved particularly in patients with small parathyroid lesions.